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INTRODUCTION
1 0 8 altered H4K5 acetylation dynamics was responsible for the impaired differentiation of 1 0 9 emerin-deficient progenitors we chose to inhibit HATs. HAT inhibitors (HATi) selected for 1 1 0 these studies were chosen because they preferentially inhibit acetylation of lysine 1 1 1 residues targeted by HDAC3 (e.g., H4K5) 34 . Cell cycle withdrawal, myosin heavy chain 1 1 2 (MyHC) expression and myotube formation were analyzed 36 hours post-differentiation 1 1 3 induction, as previously described 23 . HAT inhibitor Nu9056 was selected because it is a 1 1 4 highly specific inhibitor of histone acetyltransferase Tip60/KAT5 28 . Tip60/KAT5 mediates 1 1 5 the acetylation of H4K5, H4K8, H4K12 and H4K16ac (Table 1) . A second HAT inhibitor, 1 1 6 L002, was used to test whether inhibition of H4K5 acetylation rescued myogenic 1 1 7 differentiation of emerin-deficient progenitors. L002 inhibits H4 acetylation in cells at low 1 1 8 micromolar concentrations (Table 1) 29 . A Sirtuin 1 (SIRT1) activator (SRT1720) was 1 1 9 used to confirm the rescue of emerin-deficient progenitor differentiation was due to 1 2 0 changes in acetylation states of HDAC3 target residues (e.g., H4K5ac). Unlike HDAC3, 1 2 1 SIRT1 is an NAD+-dependent protein deacetylase 35 . SIRT1 deacetylates H3K9ac, but 1 2 2 does not affect H4K5, H4K8 or H4K12 acetylation 36 . 1.5 µM SRT1720 was added to 1 2 3 wildtype or emerin-deficient myogenic progenitors upon differentiation induction and 1 2 4 differentiation was analyzed after 36 hours ( Figure 1A ). 1 2 5 1 2 6
Concentrations of compounds used in this study were based upon the reported half-1 2 7 maximal inhibitory concentration (IC50) for each compound 28-31 and per manufacturer 1 2 8 (EMD Millipore) instructions. 0.25 µM to 30 µM or each compound was added to 1 2 9 wildtype and emerin-deficient myogenic progenitors and tested for viability and impaired 1 3 0
H4K5ac dynamics in differentiation 7 proliferation. The concentrations used in this study failed to inhibit cell proliferation and 1 3 1 had no effect on cell viability. A 1.0 mM stock solution of L002 in DMSO was added to a 1 3 2 final concentration of 0.5 µM in differentiation medium. A 1.0 mM stock solution of 1 3 3
Nu9056 in DMSO was added to a final concentration of 0.5 µM in differentiation medium.
3 4
A 3.0 mM stock solution of SRT1720 in DMSO was added to a final concentration of 1.5 1 3 5 µM in differentiation medium. Differentiation media containing each inhibitor or DMSO 1 3 6 was added to induce differentiation of wildtype or emerin-deficient myogenic progenitors. 32, 33 . Myogenic progenitors were isolated and maintained as 1 4 4 previously described 24, 33, 25 . Briefly, extensor digitorum longus (EDL) muscles were 1 4 5 isolated and placed into 2 mg/ml collagenase (Sigma, product #C0130) in DMEM 1 4 6 (Invitrogen, product #11995-065) for 1-2 hours at 35°C. Individual fibers were then 1 4 7 isolated and each fiber was transferred serially through 2-4 petri dishes containing 1 4 8 DMEM to select for undamaged fibers. Fibers were placed into matrigel-coated petri 1 4 9 dishes containing DMEM, 10% horse serum (Invitrogen product #16050-098), 0.5% 1 5 0 chick embryo extract (Accurate Chemical, product #CE6507), 2% L-Glutamine 1 5 1 (Invitrogen, product #25030-081) and 1% penicillin/streptomycin (Invitrogen, product H4K5ac dynamics in differentiation 8 strep and 20 ng/ml γ-Interferon (Millipore, product #IF005). The fibers were incubated for 1 5 7 24-48 hours at 33°C, 10% CO 2 . Upon attachment of a single myogenic progenitor to the 1 5 8 well, the fiber was removed and the myogenic progenitor was incubated in proliferation 1 5 9 media for another 48 hours at 33°C, 10% CO 2 . Approximately 200 cells are expected 1 6 0 after 48 hours and these were split and proliferated until enough cells were obtained for 1 6 1 our analyses. H2K myogenic progenitors were maintained in proliferation media at 33°C 1 6 2 and 10% CO 2 . Cells between passages 4-10 were used for these studies. Wildtype and emerin-deficient H2K myogenic progenitors were seeded onto 12 well 1 7 4 tissue culture plates coated with 0.01% gelatin (Sigma-Aldrich) for differentiation 1 7 5 induction. Cells were seeded at 23,500 cells/cm 2 in proliferation media for 24h at 33℃ 1 7 6 and 10% CO 2 . Differentiation was stimulated by replacing the proliferation medium with 1 7 7 differentiation medium (high glucose DMEM with sodium pyruvate, 5% horse serum, 2% 1 7 8 L-glutamine, ThermoFisher Scientific). The cells were maintained at 37℃ and 5% CO 2 1 7 9 throughout differentiation. Images were taken using the EVOS-FL imaging system (ThermoFisher LifeSciences) for 1 9 7 experiments with L002. The remainder of the images were taken with the EVOS-FL Auto 1 9 8 (ThermoFisher LifeSciences). All images were obtained using a long working distance Figure 1A ). Nu9056 treatment had no effect on cell cycle 2 3 7 withdrawal of wildtype or emerin-deficient myogenic progenitors, ( Figure 1C , G, J).
3 8
Nu9056 treatment failed to rescue myoblast commitment, as the number of MyHC-2 3 9 expressing cells was similar in Nu9056-treated (51.0%) and untreated emerin-deficient 2 4 0 myogenic progenitors (50.3%; Figure 1H Figure 4A, B) , comparable to H4K5ac levels in wildtype progenitors.
7 4
Nu9056 treatment decreased H4K5ac 3.2-fold in emerin-deficient myogenic progenitors 2 7 5 ( Figure 4A, B) . Decreased H4K5ac seen in emerin-deficient myogenic progenitors 2 7 6 treated with Nu9056 is similar to the H4K5ac levels seen in differentiating wildtype 2 7 7 progenitors. Western blotting confirmed the levels of H4K5ac were unchanged by 2 7 8 treatment with SRT1720 ( Figure 4C The studies presented here used a cell-based system to follow differentiation, in which 2 9 1 myotubes are formed by myoblast-to-myoblast fusion or myoblast-to-myotube fusion.
9 2
Upon stimulation of myogenic progenitors to differentiate, transcriptional reprogramming 2 9 3 is initiated, leading to cell cycle exit. This reprogramming activates the myogenic 2 9 4 differentiation program and represses the proliferative program, thereby leading to 2 9 5 myoblast commitment followed by fusion to form myotubes 37 . Transcriptional 2 9 6
reprogramming is compromised in emerin-deficient progenitors 38 . The failure of emerin-2 9 7 deficient progenitors to coordinate the temporal reorganization of their genome during 2 9 8 differentiation is predicted to cause this defective transcriptional reprogramming. The results presented here support the role of emerin in controlling histone acetylation Nu9056 exhibits high specificity, as the half-maximal inhibitory concentration (IC50) of 3 2 6
Nu9056 for Tip60/KAT5 is 20-40-fold lower than for the histone acetyltransferase p300 3 2 7 or the histone acetyltransferase pCAF/GCN5 (Table 1 ). L002 was identified as a p300-3 2 8 specific inhibitor 29 . p300 acetylates H3K18 and H3K27; it has also been reported to 3 2 9 acetylate H4K5, H4K8, H4K12 and H4K16 41, 42 . L002 was previously reported to 3 3 0 decrease H4 acetylation 29 , but this study was the first to show L002 inhibits acetylation 3 3 1 of H4K5. Although H3K9ac, H3K18ac and H3K27ac were increased in emerin-deficient 3 3 2 myogenic progenitors, treatment with Nu9056 had no significant effect on acetylation of 3 3 3 H3K9, H3K18 or H3K27; L002 treatment had a small effect on H3K18 and H3K27 3 3 4 acetylation; SRT1720 only affected H3K9 acetylation ( Figure 5) . Collectively, the distinct 3 3 5 specificities of these compounds at the concentrations used in this study demonstrates 3 3 6 that changes in acetylation of H3K9, H3K18, H3K27 and H4K16 cannot be responsible 3 3 7 for the rescued myotube formation. Rather, these results suggest rescue by L002 and 3 3 8
Nu9056 occurs primarily through rescuing H4K5 acetylation dynamics. This is consistent 3 3 9 with our previous studies using HDAC3 inhibitors and activators 23, 26 . It is possible L002 3 4 0 may act to rescue impaired myogenic commitment by p300-mediated acetylation of 3 4 1 H4K5ac dynamics in differentiation 1 6 H3K18 or H3K27 ( Figure 6 ). Alternatively, L002 may act through an unknown 3 4 2 mechanism or act on other HATs to rescue myoblast commitment, as L002 appears to 3 4 3 be more promiscuous at lower concentrations. Targeting these dynamic epigenetic 3 4 4 changes represents a new potential strategy for ameliorating the skeletal muscle wasting 3 4 5 seen in EDMD1. 
